Development of vasculature targeting strategies for the treatment of cancer and chronic inflammatory diseases

Biotechnology Annual Review

Volumn 8, Issue , 2002, Pages 133-165

  Schraa, Astrid J ^a,b   Everts, Maaike ^a   Kok, Robbert J ^a   Ásgeirsdóttir, Sigridur A ^a   Meijer, Dirk K F ^a   De Leij, Lou F M H ^a   Molema, Grietje ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Angiogenesis; Angiogenesis models; Angiopoietins; Anti angiogenic drugs; Anti inflammatory drugs; Cancer; Cell adhesion molecules; Chronic inflammation; Cytokines; Drug carriers; Drug carrier complex; FGF

Indexed keywords

ANGIOPOIETIN RECEPTOR; DRUG CARRIER; EPITOPE; FIBROBLAST GROWTH FACTOR RECEPTOR; VASCULOTROPIN RECEPTOR; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ARTHRITIS; ATHEROSCLEROSIS; CANCER THERAPY; CELL ACTIVATION; CHRONIC INFLAMMATION; DRUG TARGETING; ENDOTHELIUM CELL; ENTERITIS; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY DISEASE; REVIEW; SIGNAL TRANSDUCTION;

EID: 0346311614     PISSN: 13872656     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1387-2656(02)08007-9     Document Type: Article

References (156)

1. Molema G. Drug targeting: basic concepts and novel advances. In: Molema G, Meijer DKF (eds) Drug Targeting: Organ-specific Strategies. Weinheim: Wiley-VCH, 2001;1-22.
2. Verstraete M. Endothelial cell-mediated coagulation, anticoagulation and fibrinolysis. In: Vane JR, Born GVR, Welzel D (eds) The endothelial cell in health and disease. Stuttgart, Schattauer, 1995;147-164.
3. Ebnet K, Vestweber D. Molecular mechanisms that control leukocyte extravasation: the selectins and the chemokines. Histochem Cell Biol 1999;112:1-23.
4. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-257.
5. Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000;52:237-268.
6. Folkman J. Fighting cancer by attacking its blood supply. Scientific American 1996;116-119.
7. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364.
8. Giordano FJ, Johnson RS. Angiogenesis: the role of the microenvironment in flipping the switch. Curr Opin Genet Dev 2001;11:35-40.
9. Berra E, Milanini J, Richard DE, Le Gall M, Vinals F, Gothie E, Roux D, Pages G, Pouyssegur J. Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. Biochem Pharmacol 2000;60:1171-1178.
10. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001;21:3995-4004.
11. Ferrara N, Keyt B. Vascular endothelial growth factor: basic biology and clinical implications. EXS 1997;79:209-232.
12. Dvorak HF, Nagy JA, Feng D, Brown LF, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 1999;237:97-132.
13. Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 2000;60:203-212.
14. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-248.
15. Jones N, Iljin K, Dumont DJ, Alitalo K. Tie receptors: new modulators of angiogenic and lymphangiogenic responses. Nat Rev Mol Cell Biol 2001;2:257-267.
16. Rak J, Kerbel RS. bFGF and tumor angiogenesis - back in the limelight? Nat Med 1997;3:1083-1084.
17. Bikfalvi A, Klein S, Pintucci G, Rifkin DB. Biological roles of fibroblast growth factor-2. Endocr Rev 1997;18:26-45.
18. Czubayko F, Liaudet-Coopman ED, Aigner A, Tuveson AT, Berchem GJ, Wellstein A. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med 1997;3:1137-1140.
19. Aplin AE, Howe A, Alahari SK, Juliano RL. Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. Pharmacol Rev 1998;50:197-263.
20. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct αv integrins. Science 1995;270:1500-1502.
21. Brooks PC, Clark RAF, Cheresh DA. Requirement of vascular integrin αvβ3 for angiogenesis. Science 1994;264:569-571.
22. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KCP. Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging. Nature Med 1998;4:623-626.
23. Storgard CM, Stupack DG, Jonczyk A, Goodman SL, Fox RI, Cheresh DA. Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. J Clin Invest 1999;103:47-54.
24. Conforti G, Dominquez-Jimenez C, Zanetti A, Gimbrone MA, Cremona O, Marchisio PC, Dejana E. Human endothelial cells express integrin receptors on the luminal aspect of their membrane. Blood 1992;80:437-446.
25. Byzova TV, Rabbani R, D'Souza SE, Plow EF. Role of integrin alpha(v)beta3 in vascular biology. Thromb Haemost 1998;80:726-734.
26. Felding-Habermann B, O'Toole TE, Smith JW, Fransvea E, Ruggeri ZM, Ginsberg MH, Hughes PE, Pampori N, Shattil SJ, Saven A, Mueller BM. Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci U S A 2001;98:1853-1858.
27. Brooks PC, Monthomery AMP, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157-1164.
28. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. Antiintegrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995;96:1815-1822.
29. Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD. The codependence of angiogenesis and chronic inflammation. FASEB J 1997;11:457-465.
30. Koch AE. Review: angiogenesis: implications for rheumatoid arthritis. Arthritis Rheum 1998;41:951-962.
31. Nickoloff BJ, Mitra RS, Varani J, Dixit VM, Polverini PJ. Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol 1994;144:820-828.
32. Chen YX, Nakashima Y, Tanaka K, Shiraishi S, Nakagawa K, Sueishi K. Immunohistochemical expression of vascular endothelial growth factor/vascular permeability factor in atherosclerotic intimas of human coronary arteries. Arterioscler Thromb Vasc Biol 1999;19:131-139.
33. Bousvaros A, Leichtner A, Zurakowski D, Kwon J, Law T, Keough K, Fishman S. Elevated serum vascular endothelial growth factor in children and young adults with Crohn's disease. Dig Dis Sci 1999;44:424-430.
34. Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Yeo TK, Berse B, Jackman RW, Senger DR, Dvorak HF, Brown LF. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994;180:341-346.
35. Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, Jackman RW, Berse B, Dvorak HF. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994;180:1141-1146.
36. Inoue M, Itoh H, Ueda M, Naruko T, Kojima A, Komatsu R, Doi K, Ogawa Y, Tamura N, Takaya K, Igaki T, Yamashita J, Chun TH, Masatsugu K, Becker AE, Nakao K. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 1998;98:2108-2116.
37. Jiang BH, Zheng JZ, Aoki M, Vogt PK. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci U S A 2000;97:1749-1753.
38. Dimmeler S, Zeiher AM. Endothelial cell apoptosis in angiogenesis and vessel regression. Circ Res 2000;87:434-439.
39. Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 2001;49:568-581.
40. Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 2001;22:201-207.
41. Jones N, Dumont DJ. Tek/Tie2 signaling: new and old partners. Cancer Metastasis Rev 2000;19:13-17.
42. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211-225.
43. Giancotti FG, Ruoslahti E: Integrin signaling. Science 1999;285:1028-1032.
44. Denk A, Goebeler M, Schmid S, Berberich I, Ritz O, Lindemann D, Ludwig S, Wirth T. Activation of NFκB via the IκB kinase complex is both essential and sufficient for proinflammatory gene expression in primary endothelial cells. J Biol Chem 2001;276:28451-28458.
45. Itoh T, Arai KI. Mechanisms of signal transduction. In: Theze J (ed) The cytokine network and immune function. Oxford, Oxford University Press, 1999;169-190.
46. Herlaar E, Brown Z. p38 MAPK signalling cascades in inflammatory disease. Mol Med Today 1999;5:439-447.
47. Marumo T, Schini-Kerth VB, Busse R. Vascular endothelial growth factor activates nuclear factor-kappaB and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells. Diabetes 1999;48:1131-1137.
48. Scatena M, Almeida M, Chaisson ML, Fausto N, Nicosia RF, Giachelli CM. NFκB mediates αvβ3 integrin-induced endothelial cell survival. J Cell Biol 1998;141:1083-1093.
49. Bach FH, Hancock WW, Ferran C. Protective genes expressed in endothelial cells: a regulatory response to injury. Immunol Today 1997;18:483-486.
50. Brouard S, Otterbein LE, Anrather J, Tobiasch E, Bach FH, Choi AM, Soares MP. Carbon monoxide generated by heme oxygenase 1 suppresses endothelial cell apoptosis. J Exp Med 2000;192:1015-1026.
51. Sato H, Sugiyama Y, Tsuji A, Horikoshi I. Importance of receptor-mediated endocytosis in peptide delivery and targeting: kinetic aspects. Adv Drug Deliv Rev 1996;19:445-467.
52. Molema G, Meijer DKF (eds) Drug Targeting: Organ Specific Strategies. Weinheim: Wiley-VCH, 2001.
53. Proost JH. Pharmacokinetic/pharmacodynamic modelling in drug targeting. In: Molema G, Meijer DKF (eds) Drug Targeting: Organ-specific Strategies. Weinheim: Wiley-VCH, 2001;333-370.
54. Meijer DKF, Ziegler K. Mechanisms for the hepatic clearance of oligopeptides and proteins. Implications for rate of elimination, bioavailability and cell-specific drug delivery to the liver. In: Audus KL, Raub TJ (eds) Biological Barriers to Protein Delivery. New York: Plenum Press, 1993;339-408.
55. van der Sluijs P, Bootsma HP, Postema B, Moolenaar F, Meijer DK. Drug targeting to the liver with lactosylated albumins: does the glycoprotein target the drug or is the drug targeting the glycoprotein? Hepatology 1986;6:723-728.
56. Stehle G, Sinn H, Wunder A, Schrenk HH, Schutt S, Maier-Borst W, Heene DL. The loading rate determines tumor targeting properties of methotrexate-albumin conjugates in rats. Anticancer Drugs 1997;8:677-685.
57. Clark M. Antibody humanization: a case of the 'Emperor's new clothes'? Immunol Today 2000;21:397-402.
58. Nielsen UB, Marks JD. Internalizing antibodies and targeted cancer therapy: direct selection from phage display libraries. PSTT 2000;3:282-291.
59. Mayer A, Tsiompanou E, O'Malley D, Boxer GM, Bhatia J, Flynn AA, Chester KA, Davidson BR, Lewis AA, Winslet MC, Dhillon AP, Hilson AJ, Begent RH. Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA single-chain Fv antibody. Clin Cancer Res 2000;6:1711-1719.
60. Withoff S, Helfrich W, de Leij LF, Molema G. Bi-specific antibody therapy for the treatment of cancer. Curr Opin Mol Ther 2001;3:53-62.
61. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997;275:547-550.
62. Nettelbeck DM, Miller DW, Jerome V, Zuzarte M, Watkins SJ, Hawkins RE, Muller R, Kontermann RE. Targeting of Adenovirus to Endothelial Cells by a Bispecific Single-Chain Diabody Directed against the Adenovirus Fiber Knob Domain and Human Endoglin (CD105). Mol Ther 2001;3:882-891.
63. Ruoslahti E, Rajotte D. An address system in the vasculature of normal tissues and tumors. Annu Rev Immunol 2000;18:813-827.
64. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279:377-380.
65. Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, Ashmun RA, Shapiro LH, Arap W, Ruoslahti E. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000;60:722-727.
66. Koivunen E, Arap W, Valtanen H, Rainisalo A, Medina OP, Heikkila P, Kantor C, Gahmberg CG, Salo T, Konttinen YT, Sorsa T, Ruoslahti E, Pasqualini R. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 1999;17:768-774.
67. Pfaff M, Tangemann K, Muller B, Gurrath M, Muller G, Kessler H, Timpl R, Engel J. Selective recognition of cyclic RGD peptides of NMR defined conformation by αIIbβ3, αvβ3, and α5β1 integrins. J Biol Chem 1994;269:20233-20238.
68. Koivunen E, Wang B, Ruoslahti E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Bio/Technology 1995;13:265-270.
69. Fukuda MN, Ohyama C, Lowitz K, Matsuo O, Pasqualini R, Ruoslahti E, Fukuda M. A peptide mimic of E-selectin ligand inhibits sialyl Lewis X-dependent lung colonization of tumor cells. Cancer Res 2000;60:450-456.
70. Insug O, Kieber-Emmons T, Otvos L Jr., Blaszczyk-Thurin M. Peptides mimicking sialyl-Lewis A isolated from a random peptide library and peptide array. Ann NY Acad Sci 1999;886:276-279.
71. Welply JK, Abbas SZ, Scudder P, Keene JL, Broschat K, Casnocha S, Gorka C, Steininger C, Howard SC, Schmuke JJ. Multivalent sialyl-LeX: potent inhibitors of E-selectin-mediated cell adhesion; reagent for staining activated endothelial cells. Glycobiology 1994;4:259-265.
72. Ramakrishnan S, Olson TA, Bautch VL, Mohanraj D. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res 1996;56:1324-1330.
73. Olson TA, Mohanraj D, Roy S, Ramakrishnan S. Targeting the tumor vasculature: inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate. Int J Cancer 1997;73:865-870.
74. Arora N, Masood R, Zheng T, Cai J, Smith DL, Gill PS. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Res 1999;59:183-188.
75. Wild R, Dhanabal M, Olson TA, Ramakrishnan S. Inhibition of angiogenesis and tumour growth by VEGF121-toxin conjugate: differential effect on proliferating endothelial cells. Br J Cancer 2000;83:1077-1083.
76. Meijer DKF, Molema G, Moolenaar F, De Zeeuw D, Swart PJ. (Glyco)-protein drug carriers with an intrinsic therapeutic activity: The concept of dual targeting. J Contr Rel 1996;39:163-172.
77. Kuijpers TW, Raleigh M, Kavanagh T, Janssen H, Calafat J, Roos D, Harlan JM. Cytokine-activated endothelial cells internalize E-selectin into a lysosomal compartment of vesiculotubular shape. A tubulin-driven process. J Immunol 1994;152:5060-5069.
78. Muzykantov VR. Targeting of superoxide dismutase and catalase to vascular endothelium. J Control Release 2001;71:1-21.
79. Nilsson F, Kosmehl H, Zardi L, Neri D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 2001;61:711-716.
80. Demartis S, Tarli L, Borsi L, Zardi L, Neri D. Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin. Eur J Nucl Med 2001;28:534-539.
81. Verkarre V, Patey-Mariaud dS, Vazeux R, Teillac-Hamel D, Chretien-Marquet B, Le Bihan C, Leborgne M, Fraitag S, Brousse N. ICAM-3 and E-selectin endothelial cell expression differentiate two phases of angiogenesis in infantile hemangiomas. J Cutan Pathol 1999;26:17-24.
82. Murdoch C, Finn A. Chemokine receptors and their role in inflammation and infectious diseases. Blood 2000;95:3032-3043.
83. Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, Rio GD, Krajewski S, Lombardo CR, Rao R, Ruoslahti E, Bredesen DE, Pasqualini R. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 1999;5:1032-1038.
84. Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 2000;18:1185-1190.
85. Haubner R, Wester HJ, Weber WA, Mang C, Ziegler SI, Goodman SL, Senekowitsch-Schmidtke R, Kessler H, Schwaiger M. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F- labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001;61:1781-1785.
86. van Hagen PM, Breeman WA, Bernard HF, Schaar M, Mooij CM, Srinivasan A, Schmidt MA, Krenning EP, de Jong M. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int J Cancer 2000;90:186-198.
87. Seon BK, Matsuno F, Haruta Y, Kondo M, Barcos M. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin Cancer Res 1997;3:1031-1044.
88. Matsuno F, Haruta Y, Kondo M, Tsai H, Barcos M, Seon BK. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin Cancer Res 1999;5:371-382.
89. Tabata M, Kondo M, Haruta Y, Seon BK. Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using (125)I-labeled anti-endoglin monoclonal antibodies. Int J Cancer 1999;82:737-742.
90. Bredow S, Lewin M, Hofmann B, Marecos E, Weissleder R. Imaging of tumour neovasculature by targeting the TGF-beta binding receptor endoglin. Eur J Cancer 2000;36:675-681.
91. Ran S, Gao B, Duffy S, Watkins L, Rote N, Thorpe PE. Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res 1998;58:4646-4653.
92. Cooke SP, Boxer GM, Lawrence L, Pedley RB, Spencer DI, Begent RH, Chester KA. A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: receptor complex. Cancer Res 2001;61:3653-3659.
93. Kiely JM, Cybulsky MI, Luscinskas FW, Gimbrone MA Jr. Immunoselective targeting of an anti-thrombin agent to the surface of cytokine-activated vascular endothelial cells. Arterioscler Thromb Vasc Biol 1995;15:1211-1218.
94. Spragg DD, Alford DR, Greferath R, Larsen CE, Lee KD, Gurtner GC, Cybulsky MI, Tosi PF, Nicolau C, Gimbrone MA. Immunotargeting of liposomes to activated vascular endothelial cells: A strategy for site-selective delivery in the cardiovascular system. Proc Natl Acad Sci USA 1997;94:8795-8800.
95. Jamar F, Chapman PT, Manicourt DH, Glass DM, Haskard DO, Peters AM. A comparison between 111In-anti-E-selectin mAb and 99Tcm- labelled human non-specific immunoglobulin in radionuclide imaging of rheumatoid arthritis. Br J Radiol 1997;70:473-481.
96. Harari OA, Wickham TJ, Stocker CJ, Kovesdi I, Segal DM, Huehns TY, Sarraf C, Haskard DO. Targeting an adenoviral gene vector to cytokine-activated vascular endothelium via E-selectin. Gene Ther 1999;6:801-807.
97. Huss WJ, Hanrahan CF, Barrios RJ, Simons JW, Greenberg NM. Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res 2001;61:2736-2743.
98. Dougher M, Terman BI. Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization. Oncogene 1999;18:1619-1627.
99. Savill J, Dransfield I, Hoff N, Haslett C. Vitronectin receptor-mediated phagocytosis of cells undergoing apoptosis. Nature 1990;343:170-173.
100. Mutuberria R, Arends JW, Griffioen AW, Hoogenboom HR. Phage display technology for target discovery in drug delivery research. In: Molema G, Meijer DKF (eds) Drug Targeting: Organ-specific Strategies. Weinheim: Wiley-VCH, 2001;255-274.
101. Yamamoto M, Wakatsuki T, Hada A, Ryo A. Use of serial analysis of gene expression (SAGE) technology. J Immunol Methods 2001;250:45-66.
102. De Waard V, van den Berg BM, Veken J, Schultz-Heienbrok R, Pannekoek H, van Zonneveld AJ. Serial analysis of gene expression to assess the endothelial cell response to an atherogenic stimulus. Gene 1999;226:1-8.
103. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B, Kinzler KW. Genes expressed in human tumor endothelium. Science 2000;289:1197-1202.
104. Lockhart DJ, Winzeler EA. Genomics, gene expression and DNA arrays. Nature 2000;405:827-836.
105. Kok RJ, Ásgeirsdóttir SA, Verweij WR. Development of proteinaceous drug targeting constructs using chemical and recombinant DNA approaches. In: Molema G, Meijer DKF (eds) Drug Targeting: Organ-specific Strategies. Weinheim: Wiley-VCH, 2001;275-308.
106. Lloyd JB. Lysosome membrane permeability: implications for drug delivery. Adv Drug Deliv Rev 2000;41:189-200.
107. Moghimi SM, Rajabi-Siahboomi AR. Recent advances in cellular, sub-cellular and molecular targeting. Adv Drug Deliv Rev 2000;41:129-133.
108. Sedlacek HH. Pharmacological aspects of targeting cancer gene therapy to endothelial cells. Crit Rev Oncol Hematol 2001;37:169-215.
109. Luo D, Saltzman WM. Synthetic DNA delivery systems. Nat Biotechnol 2000;18:33-37.
110. Hagedorn M, Bikfalvi A. Target molecules for anti-angiogenic therapy: from basic research to clinical trials. Crit Rev Oncol Hematol 2000;34:89-110.
111. McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist 2000;5 Suppl 1:3-10.
112. Wang Y, Becker D. Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat Med 1997;3:887-893.
113. Auguste P, Gursel DB, Lemiere S, Reimers D, Cuevas P, Carceller F, Di Santo JP, Bikfalvi A. Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and -independent mechanisms. Cancer Res 2001;61:1717-1726.
114. Bell CJ, Wallace JL. Inflammatory Bowel Disorders. Current and Future Drugs That Modulate Adhesion Molecules. BioDrugs 1997;7:273-284.
115. Brostjan C, Anrather J, Csizmadia V, Natarajan G, Winkler H. Glucocorticoids inhibit E-selectin expression by targeting NF-kappaB and not ATF/c-Jun. J Immunol 1997;158:3836-3844.
116. Mori N, Horie Y, Gerritsen ME, Anderson DC, Granger DN. Anti-inflammatory drugs and endothelial cell adhesion molecule expression in murine vascular beds. Gut 1999;44:186-195.
117. Liu SF, Ye X, Malik AB. Pyrrolidine dithiocarbamate prevents I-kappaB degradation and reduces microvascular injury induced by lipopolysaccharide in multiple organs. Mol Pharmacol 1999;55:658-667.
118. Faruqi RM, Poptic EJ, Faruqi TR, De La Motte C, DiCorleto PE. Distinct mechanisms for N-acetylcysteine inhibition of cytokine- induced E-selectin and VCAM-1 expression. Am J Physiol 1997;273:H817-H826.
119. Castro A, Sengupta TK, Ruiz DC, Yang E, Ivashkiv LB. IL-4 selectively inhibits IL-2-triggered Stat5 activation, but not proliferation, in human T cells. J Immunol 1999;162:1261-1269.
120. Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, Nishimoto N, Kajita T, Taga T, Yoshizaki K, Akira S, Kishimoto T. Structure and function of a new STAT-induced STAT inhibitor. Nature 1997;387:924-929.
121. Sakamoto H, Yasukawa H, Masuhara M, Tanimura S, Sasaki A, Yuge K, Ohtsubo M, Ohtsuka A, Fujita T, Ohta T, Furukawa Y, Iwase S, Yamada H, Yoshimura A. A Janus kinase inhibitor, JAB, is an interferon-gamma-inducible gene and confers resistance to interferons. Blood 1998;92:1668-1676.
122. Levitzki A. Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol Ther 1999;82:231-239.
123. Gupta K, Ramakrishnan S, Browne PV, Solovey A, Hebbel RP. A novel technique for culture of human dermal microvascular endothelial cells under either serum-free or serum-supplemented conditions: isolation by panning and stimulation with vascular endothelial growth factor. Exp Cell Res 1997;230:244-251.
124. Richard L, Velasco P, Detmar M. A simple immunomagnetic protocol for the selective isolation and long-term culture of human dermal microvascular endothelial cells. Exp Cell Res 1998;240:1-6.
125. Haraldsen G, Rugtveit J, Kvale D, Scholz T, Muller WA, Hovig T, Brandtzaeg P. Isolation and longterm culture of human intestinal microvascular endothelial cells. Gut 1995;37:225-234.
126. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 1996;380:364-366.
127. Kluger MS, Johnson DR, Pober JS. Mechanism of sustained E-selectin expression in cultured human dermal microvascular endothelial cells. J Immunol 1997;158:887-896.
128. Yashima R, Abe M, Tanaka K, Ueno H, Shitara K, Takenoshita S, Sato Y. Heterogeneity of the signal transduction pathways for VEGF-induced MAPKs activation in human vascular endothelial cells. J Cell Physiol 2001;188:201-210.
129. Edgell CJ, McDonald CC, Graham JB. Permanent cell line expressing human factor VHI-related antigen established by hybridization. Proc Natl Acad Sci U S A 1983;80:3734-3737.
130. Ades EW, Candal FJ, Swerlick RA, George VG, Summers S, Bosse DC, Lawley TJ. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 1992;99:683-690.
131. van Leeuwen EB, Wisman GB, Tervaert JW, Palmans LL, van Wijk RT, Veenstra R, Molema G, van der Zee AG, van der Meer J, Ruiters MH. An SV40 large T-antigen immortalized human umbilical vein endothelial cell line for anti-endothelial cell antibody detection. Clin Exp Rheumatol 2001;19:283-290.
132. Rood PM, Calafat J, dem Borne AE, Gerritsen WR, van der Schoot CE. Immortalisation of human bone marrow endothelial cells: characterisation of new cell lines. Eur J Clin Invest 2000;30:618-629.
133. Yang J, Chang E, Cherry AM, Bangs CD, Oei Y, Bodnar A, Bronstein A, Chiu CP, Herron GS. Human endothelial cell life extension by telomerase expression. J Biol Chem 1999;274:26141-26148.
134. O'Hare MJ, Bond J, Clarke C, Takeuchi Y, Atherton AJ, Berry C, Moody J, Silver AR, Davies DC, Alsop AE, Neville AM, Jat PS. Conditional immortalization of freshly isolated human mammary fibroblasts and endothelial cells. Proc Natl Acad Sci U S A 2001;98:646-651.
135. Brown J, Reading SJ, Jones S, Fitchett CJ, Howl J, Martin A, Longland CL, Michelangeli F, Dubrova YE, Brown CA. Critical evaluation of ECV304 as a human endothelial cell model defined by genetic analysis and functional responses: a comparison with the human bladder cancer derived epithelial cell line T24/83. Lab Invest 2000;80:37-45.
136. Garlanda C, Parravicini C, Sironi M, De Rossi M, Wainstok dC, Carozzi F, Bussolino F, Colotta F, Mantovani A, Vecchi A. Progressive growth in immunodeficient mice and host cell recruitment by mouse endothelial cells transformed by polyoma middle-sized T antigen: implications for the pathogenesis of opportunistic vascular tumors. Proc Natl Acad Sci USA 1994;91:7291-7295.
137. Dong QG, Bernasconi S, Lostaglio S, De Calmanovici RW, Martin-Padura I, Breviario F, Garlanda C, Ramponi S, Mantovani A, Vecchi A. A general strategy for isolation of endothelial cells from murine tissues. Characterization of two endothelial cell lines from the murine lung and subcutaneous sponge implants. Arterioscler Thromb Vasc Biol 1997;17:1599-1604.
138. Marelli-Berg FM, Peek E, Lidington EA, Stauss HJ, Lechler RI. Isolation of endothelial cells from murine tissue. J Immunol Methods 2000;244:205-215.
139. Thorens B, Vassalli P. Chloroquine and ammonium chloride prevent terminal glycosylation of immunoglobulins in plasma cells without affecting secretion. Nature 1986;321:618-620.
140. Wileman T, Boshans RL, Schlesinger P, Stahl P. Monensin inhibits recycling of macrophage mannose-glycoprotein receptors and ligand delivery to lysosomes. Biochem J 1984;220:665-675.
141. Memmo LM, McKeown-Longo P. The alphavbeta5 integrin functions as an endocytic receptor for vitronectin. J Cell Sci 1998;111:425-433.
142. Melgert BN, Olinga P, Weert B, Slooff MJ, Meijer DK, Poelstra K, Groothuis GM. Cellular distribution and handling of liver-targeting preparations in human livers studied by a liver lobe perfusion. Drug Metab Dispos 2001;29:361-367.
143. Jain RK, Schlenger K, Hockel M, Yuan F. Quantitative angiogenesis assays: progress and problems. Nat Med 1997;3:1203-1208.
144. Keelan ETM, Licence ST, Peters AM, Binns RM, Haskard DO. Characterization of E-selectin expression in vivo with use of a radiolabeled monoclonal antibody. Am J Physiol 1994;266:H278-90.
145. Grabbe S, Schwarz T. Immunoregulatory mechanisms involved in elicitation of allergic contact hypersensitivity. Immunol Today 1998;19:37-44.
146. Silber A, Newman W, Reimann KA, Hendricks E, Walsh D, Ringler DJ. Kinetic expression of endothelial adhesion molecules and relationship to leukocyte recruitment in two cutaneous models of inflammation. Lab Invest 1994;70:163-175.
147. Horizoe T, Nagakura N, Chiba K, Shirota H, Shinoda M, Numata H, Kobayashi S, Abe C. Effects of ER-34122, a novel dual 5-lipoxygenase/cyclooxygenase inhibitor, on indices of early articular lesion in MRL/MpJ-lpr/lpr mice. Inflamm Res 1999;48:432-436.
148. de Bandt M, Grossin M, Weber AJ, Chopin M, Elbim C, Pla M, Gougerot-Pocidalo MA, Gaudry M. Suppression of arthritis and protection from bone destruction by treatment with TNP-470/AGM-1470 in a transgenic mouse model of rheumatoid arthritis. Arthritis Rheum 2000;43:2056-2063.
149. Tominaga K, Alstergren P, Kurita H, Matsukawa A, Fukuda J, Kopp S. Interleukin-1beta in antigen-induced arthritis of the rabbit temporomandibular joint. Arch Oral Biol 2001;46:539-544.
150. Joe B, Wilder RL. Animal models of rheumatoid arthritis. Mol Med Today 1999;5:367-369.
151. Smith JD, Breslow JL. The emergence of mouse models of atherosclerosis and their relevance to clinical research. J Intern Med 1997;242:99-109.
152. Cybulsky MI, Gimbrone MA Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991;251:788-791.
153. Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastro 1995;109:1344-1367.
154. Hamamoto N, Maemura K, Hirata I, Murano M, Sasaki S, Katsu K. Inhibition of dextran sulphate sodium (DSS)-induced colitis in mice by intracolonically administered antibodies against adhesion molecules (endothelial leucocyte adhesion molecule-1 (ELAM-1) or intercellular adhesion molecule-1 (ICAM-1)). Clin Exp Immunol 1999;117:462-468.
155. Soriano A, Salas A, Salas A, Sans M, Gironella M, Elena M, Anderson DC, Pique JM, Panes J. VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockade ameliorates DSS- induced colitis in mice. Lab Invest 2000;80:1541-1551.
156. Sun FF, Lai PS, Yue G, Yin K, Nagele RG, Tong DM, Krzesicki RF, Chin JE, Wong PY. Pattern of cytokine and adhesion molecule mRNA in hapten-induced relapsing colon inflammation in the rat. Inflammation 2001;25:33-45.